Scarica l'app Stockscreener
14.46
0.21%
0.03
Dopo l'orario di chiusura:
14.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$14.43
Aprire:
$14.43
Volume 24 ore:
2.62M
Relative Volume:
0.40
Capitalizzazione di mercato:
$4.54B
Reddito:
$634.21M
Utile/perdita netta:
$-27.11M
Rapporto P/E:
-163.39
EPS:
-0.0885
Flusso di cassa netto:
$29.85M
1 W Prestazione:
+0.35%
1M Prestazione:
+0.63%
6M Prestazione:
+83.50%
1 anno Prestazione:
+77.21%
Intervallo 1D:
$14.42
$14.46
Intervallo di 1 settimana:
$14.40
$14.46
Portata 52W:
$5.51
$14.46
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.46 | 4.53B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
446.54 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
772.64 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
730.25 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.87 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.52 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-29 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | Downgrade | TD Cowen | Buy → Hold |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics stock hits 52-week high at $14.44 By Investing.com - Investing.com India
EPS Watch: Is Amicus Therapeutics Inc in a bullish channelMarket Sentiment Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return - Yahoo Finance
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd - MarketBeat
FOLD PE Ratio & Valuation, Is FOLD Overvalued - intellectia.ai
Recap Report: What is the long term forecast for Amicus Therapeutics Inc stockQuarterly Market Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Vanguard disaggregates holdings, reports 0% in Amicus (NASDAQ: FOLD) - Stock Titan
JPMorgan Chase & Co. Sells 94,105 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
ETFs investiert in Amicus Therapeutics, Inc.-Aktien - TradingView
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighWhat's Next? - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com
Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Biotechnology Index - marketscreener.com
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month HighTime to Buy? - MarketBeat
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis - PR Newswire
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW) - msn.com
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance
Amicus Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market - Stock Titan
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - BioWorld MedTech
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price? - simplywall.st
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):